在菲尔戈提尼布治疗期间性结肠炎的症状反应的不同轨迹:从SELECTION研究中进行的后期分析
Stefan Schreiber1, Brian G Feagan2,3, Edouard Louis4
1Department of Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.
治疗性结肠炎的菲尔戈提尼布显示出不同的患者反应轨迹. 在基线较不严重的生物学上天真的患者经历了更有益的长期结果与filgotinib.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 菲尔戈提尼布是一种口服的Janus激酶1优先抑制剂,用于性结肠炎 (UC).
- 识别长期治疗反应模式可以优化UC管理.
- 在SELECTION试验中,评估了菲尔戈提尼布在UC患者中的疗效.
研究的目的:
- 根据部分梅奥诊所得分 (pMCS) 轨迹在费尔戈提尼布治疗期间识别和描述不同的患者子组.
- 在UC中分析影响长期对filgotinib反应的因素.
- 评估在不同应对轨迹中实现综合疾病控制 (CDC) 的成就.
主要方法:
- 对SELECTION试验数据的后期分析.
- 基于组的轨迹建模 (GBTM) 应用于pMCS数据,直到第58周.
- 在轨道组之间比较患者人口统计,疾病特征和早期反应标志物.
主要成果:
- 使用GBTM确定了五种不同的患者反应轨迹,其中67.5%显示有益的轨迹.
- 有益的轨迹与生物无知,最近的诊断和200毫克的菲尔戈提尼布剂量有关.
- 在55.4%的患者中观察到的持续有益轨迹与较低的基线内镜评分和强烈的第10周FCP反应有关.
结论:
- 使用菲尔戈提尼布的长期有益反应和综合疾病控制 (CDC) 与生物原始状态和较不严重的基线疾病有关.
- 早期识别持续响应者和CDC的成就可以指导个性化的UC管理策略.
- 了解filgotinib的反应轨迹有助于定制性结肠炎的治疗方法.
更多相关视频
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
